Bullish Case: Calls outtraded puts 10% at the 1st-volume percentile, signaling quiet accumulation rather than distribution. Helium's price-density function concentrates mass at $4.0–$4.5 (~+15–25% above $3.54), its $2 downside density (0.0373) is less than half the market's (0.0796), and short-dated IV compressing to 21–48% post-earnings fits an IV-crush-then-drift-up regime if rescheduling resumes.

Bearish Case: Post-Q1 drift after a weak print (5% cannabis growth, $16.5M op loss, sub-$600M cap), DEA rescheduling paused, -79% YoY, and -26% over 60 days. Market IV spikes to 145–160% on Nov 7 and Nov 28 term dates show event-like downside risk, and the market prices a heavier $2 tail than Helium — dilution or further delay could break $3.

Potential Outcomes: 45% $3.2–$3.9 chop: flat post-earnings regime holds; falsifiable if spot exits range within 2 weeks.
25% drift to $2.8–$3.2: put flow/dilution; falsifiable if $3 holds and Nov IV compresses.
18% rally to $4.0–$4.5: rescheduling hearing reschedules; oracle = Nov 7/28 IV spikes crush while spot >$3.7.
9% >$5 on rescheduling/regulatory headline.
3% <$2.5 on dilution/severe surprise.

October 10, 2026